Sarepta Therapeutics
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did not meet the primary endpoint.
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Sarepta Licenses Clinical, Preclinical siRNA Candidates From Arrowhead, Enters Discovery Deal
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
Sarepta Stops Duchenne Drug Development; Nets Higher-Than-Expected Elevidys Q3 Sales
The firm is discontinuing its SRP-5051 development program but recorded $181.0 million in Elevidys sales.